Literature DB >> 29896034

Comparative Review of Oral P2Y12 Inhibitors.

Renee Koski, Blake Kennedy.   

Abstract

Current practice guidelines recommend dual antiplatelet therapy comprised of aspirin and a purinergic signaling receptor Y12 (P2Y12) for patients following acute coronary syndrome. This article compares the efficacy, safety, and other characteristics of the three available oral P2Y12 inhibitors-clopidogrel, prasugrel, and ticagrelor.

Entities:  

Keywords:  P2Y12 inhibitors; acute coronary syndrome; antiplatelet; clopidogrel; prasugrel; ticagrelor

Year:  2018        PMID： 29896034      PMCID： PMC5969212     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  43 in total

1.  Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.

Authors:  Patricia A Cowper; Wenqin Pan; Kevin J Anstrom; Padma Kaul; Lars Wallentin; Linda Davidson-Ray; Elisabet Nikolic; Magnus Janzon; Lars-Åke Levin; Christopher P Cannon; Robert A Harrington; Daniel B Mark
Journal:  J Am Coll Cardiol       Date:  2015-02-10       Impact factor: 24.094

2.  Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Kenneth W Mahaffey; Daniel M Wojdyla; Kevin Carroll; Richard C Becker; Robert F Storey; Dominick J Angiolillo; Claes Held; Christopher P Cannon; Stefan James; Karen S Pieper; Jay Horrow; Robert A Harrington; Lars Wallentin
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

Review 3.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.

Authors:  Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

Review 4.  Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.

Authors:  Leonardo De Luca; Piera Capranzano; Giuseppe Patti; Guido Parodi
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

5.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.

Authors:  Dirk Sibbing; Dániel Aradi; Claudius Jacobshagen; Lisa Gross; Dietmar Trenk; Tobias Geisler; Martin Orban; Martin Hadamitzky; Béla Merkely; Róbert Gábor Kiss; András Komócsi; Csaba A Dézsi; Lesca Holdt; Stephan B Felix; Radoslaw Parma; Mariusz Klopotowski; Robert H G Schwinger; Johannes Rieber; Kurt Huber; Franz-Josef Neumann; Lukasz Koltowski; Julinda Mehilli; Zenon Huczek; Steffen Massberg
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

6.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

7.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

8.  Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.

Authors:  Keith A A Fox; Shamir R Mehta; Ron Peters; Feng Zhao; Nasser Lakkis; Bernard J Gersh; Salim Yusuf
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

9.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Stefan K James; Matthew T Roe; Christopher P Cannon; Jan H Cornel; Jay Horrow; Steen Husted; Hugo Katus; Joao Morais; Ph Gabriel Steg; Robert F Storey; Susanna Stevens; Lars Wallentin; Robert A Harrington
Journal:  BMJ       Date:  2011-06-17

10.  Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Authors:  Christopher P Cannon; Savion Gropper; Deepak L Bhatt; Stephen G Ellis; Takeshi Kimura; Gregory Y H Lip; Ph Gabriel Steg; Jurriën M Ten Berg; Jenny Manassie; Jörg Kreuzer; Jon Blatchford; Joseph M Massaro; Martina Brueckmann; Ernesto Ferreiros Ripoll; Jonas Oldgren; Stefan H Hohnloser
Journal:  Clin Cardiol       Date:  2016-08-26       Impact factor: 2.882
View more
  8 in total

1.  P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.

Authors:  Junzhe Chen; Ying Tang; Yu Zhong; Biao Wei; Xiao-Ru Huang; Patrick Ming-Kuen Tang; Anping Xu; Hui-Yao Lan
Journal:  Mol Ther       Date:  2022-07-05       Impact factor: 12.910

Review 2.  The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.

Authors:  Davide Ferrari; Michele Rubini; Jorge S Burns
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

3.  Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades.

Authors:  Claudia Penna; Manuela Aragno; Alessia Sofia Cento; Saveria Femminò; Isabella Russo; Federica Dal Bello; Fausto Chiazza; Debora Collotta; Gustavo Ferreira Alves; Massimo Bertinaria; Elisa Zicola; Valentina Mercurio; Claudio Medana; Massimo Collino; Pasquale Pagliaro
Journal:  Oxid Med Cell Longev       Date:  2020-08-03       Impact factor: 6.543

4.  Phosphorylation of protein kinase Cδ positively regulates thromboxane generation in platelets.

Authors:  John C Kostyak; Benjamin Mauri; Akruti Patel; Carol Dangelmaier; Haritha Reddy; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2021-04-28       Impact factor: 5.157

5.  Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain.

Authors:  Berend van der Wildt; Bieneke Janssen; Aleksandra Pekošak; E Johanna L Stéen; Robert C Schuit; Esther J M Kooijman; Wissam Beaino; Danielle J Vugts; Albert D Windhorst
Journal:  ACS Chem Neurosci       Date:  2021-11-10       Impact factor: 4.418

Review 6.  Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Physiol Rev       Date:  2020-10-30       Impact factor: 37.312

Review 7.  The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.

Authors:  Olubadewa A Fatunde; Sherry-Ann Brown
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

8.  Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.

Authors:  Eva Lesén; Christopher Hewitt; Evangelos Giannitsis; Jonatan Hedberg; Tomas Jernberg; Dimitra Lambrelli; Aldo P Maggioni; Jason C Simeone; Albert Ariza-Solé; Robert F Storey; Jurrien Ten Berg; Marc Bonaca
Journal:  Clin Cardiol       Date:  2021-08-08       Impact factor: 2.882
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.